Genmab — April 2016
-
forventer ikke prispres på produkter med "significant unmet need"
-
det var det - Dara fik en ret prominent plads i præsentationen på trods af det begrænsede bidrag til totalomsætningen. Den skal nok blive spændende at følge i næste rapportering

-
Fred være med det. Den skal nok komme.
-
Blogbuster: As part of their J&J coverage, Cowen (a well-known US healthcare investment boutique) commented on the 1st quarter Dara-sales…
-
Det vil jeg være glad for. Lagde hovedet på blokken med et bud på 500-600 mio i Børsen Play i februar.

-
typisk genmab ,, positive meldninger og så skal vi falde ,,, nu må de gerne lukke de shorts
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
️